2692623-81-5
Chemical Structure
D-erythro-Sphingosine-13C2,d2
Synonym(s): Erythrosphingosine-13C2,d2; erythro-C18-Sphingosine-13C2,d2; trans-4-Sphingenine-13C2,d2
- CAS No.: 2692623-81-5
- Formula:C1613C2H35D2NO2
- Molecular Weight:303.49
IUPAC Name: (2S,3R,E)-2-aminooctadec-4-ene-1,2-13C2-1,1-d2-1,3-diol
InChIKey: WWUZIQQURGPMPG-IMIVUYSRSA-N
SMILES: CCCCCCCCCCCCC/C=C/[C@@H](O)[13C@@H](N)[13C]([2H])([2H])O
Biological Activity: D-erythro-Sphingosine-13C2,d2 is a deuterated labeled D-erythro-Sphingosine[1]. D-erythro-Sphingosine (Erythrosphingosine) is a very potent activator of p32-kinase with an EC50 of 8 μM, and inhibits protein kinase C (PKC). D-erythro-Sphingosine (Erythrosphingosine) is also a PP2A activator[2][3][4][5].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
D-erythro-Sphingosine-13C2,d2 | D-erythro-Sphingosine-13C2,d2 is a deuterated labeled D-erythro-Sphingosine. D-erythro-Sphingosine (Erythrosphingosine) is a very potent activator of p32-kinase with an EC50 of 8 μM, and inhibits protein kinase C (PKC). D-erythro-Sphingosine (Erythrosphingosine) is also a PP2A activator. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
D-erythro-Sphingosine (Standard) | 99.96% | D-erythro-Sphingosine (Standard) is the analytical standard of D-erythro-Sphingosine. This product is intended for research and analytical applications. D-erythro-Sphingosine (Erythrosphingosine) is a very potent activator of p32-kinase with an EC50 of 8 μM, and inhibits protein kinase C (PKC). D-erythro-Sphingosine (Erythrosphingosine) is also a PP2A activator. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
D-erythro-Sphingosine-d7 | 99.0% | D-erythro-Sphingosine-d7 is the deuterium labeled D-erythro-Sphingosine. D-erythro-Sphingosine (Erythrosphingosine) is a very potent activator of p32-kinase with an EC50 of 8 μM, and inhibits protein kinase C (PKC). D-erythro-Sphingosine (Erythrosphingosine) is also a PP2A activator. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
D-erythro-Sphingosine | 98.0% | D-erythro-Sphingosine (Erythrosphingosine) is a very potent activator of p32-kinase with an EC50 of 8 μM, and inhibits protein kinase C (PKC). D-erythro-Sphingosine (Erythrosphingosine) is also a PP2A activator. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [Content Brief]
- [2]. Cheng P, et al. Protein phosphatase 2A (PP2A) activation promotes axonal growth and recovery in the CNS. J Neurol Sci. 2015 Dec 15;359(1-2):48-56. [Content Brief]
- [3]. Pushkareva MYu, et al. Regulation of sphingosine-activated protein kinases: selectivity of activation by sphingoid basesand inhibition by non-esterified fatty acids. Biochem J. 1993 Sep 15;294 ( Pt 3):699-703. [Content Brief]
- [4]. Khan WA, et al. Protein kinase C and platelet inhibition by D-erythro-Sphingosine: comparison with N,N-dimethylsphingosine and commercial preparation. Biochem Biophys Res Commun. 1990 Oct 30;172(2):683-91. [Content Brief]
- [5]. Pham VT, et al. A concise synthesis of a promising protein kinase C inhibitor: D-erythro-Sphingosine. Arch Pharm Res. 2007 Jan;30(1):22-7. [Content Brief]
